Genprex Stock Price - GNPX

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
After Hours
Last Trade
Last $ 1.21 ▼ -0.07 (-5.47%)
Company Name Stock Ticker Symbol Market Type
Genprex Inc GNPX NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.12 -8.57% 1.28 1.50 1.25 1.38 1.40 00:00:03
Bid Price Ask Price Spread Spread % News
1.15 1.28 0.13 10.16% 2 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
13,624 5,228,119 $ 1.30 $ 6,808,338 4,835,091 0.231 - 2.49
Last Trade Time Type Quantity Stock Price Currency
19:59:15 formt 2,000 $ 1.21 USD

Genprex Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 24.66M 19.27M $ -12.37M -0.89 - 18.65M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 3.90%

more financials information »

Genprex News

Loading Messages....

Latest GNPX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GNPX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.37492.250.34231.4729,956,1760.9051241.42%
1 Month0.272.250.261.317,341,3051.01374.07%
3 Months0.522.250.2311.182,830,3290.76146.15%
6 Months1.082.250.2311.171,295,0310.2018.52%
1 Year1.552.490.2311.18689,081-0.27-17.42%
3 Years4.6919.44990.2312.31439,652-3.41-72.71%
5 Years4.6919.44990.2312.31439,652-3.41-72.71%

Genprex Description

Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.


Your Recent History
NASDAQ
GNPX
Genprex
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.